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INTRODUCTION
Chorionicity is the main determinant of perinatal outcome in twin pregnancy. Monochorionic (MC) twin pregnancies are at higher risk of perinatal mortality and morbidity compared with dichorionic (DC) pregnancies due to the excess risk of preterm birth, growth discordance and complications unique to MC placentas, such as twin-twin transfusion syndrome (TTTS), twin reversed arterial perfusion (TRAP) sequence and selective intrauterine growth restriction [1] [2] [3] [4] [5] [6] [7] . Prenatal identification of monochorionic monoamniotic (MCMA) twins is fundamental because monoamnionicity carries a further increased risk of adverse pregnancy outcome compared with MC diamniotic pregnancies, thus ideally requiring a tailored approach 8 . Despite this, the optimal type of management of MCMA pregnancy has still to be elucidated. There is no randomized controlled trial addressing the type and frequency of follow-up in MCMA pregnancy, and no specific recommendation on how to manage MCMA twins has been provided by the different national bodies. MCMA pregnancies are usually delivered between 32 and 34 weeks of gestation in view of the reported high risk of unexpected fetal loss with advancing gestation 9 . The antenatal management protocol of monoamniotic twins is also controversial, with some studies advocating inpatient follow-up of these pregnancies with serial ultrasound and cardiotocographic (CTG) assessment, while others report no difference in the perinatal outcome between cases managed as inpatients and those managed as outpatients 9 . However, published studies are likely to be biased by their retrospective design, small sample size and inclusion of cases with fetal anomalies, thus making it difficult to extrapolate robust evidence of the actual risk of perinatal mortality in these pregnancies.
The primary aim of this systematic review was to quantify the incidence of perinatal mortality in MCMA twin pregnancies, according to gestational age. The secondary aim was to ascertain the risk of mortality in pregnancies managed as inpatients compared with those managed as outpatients.
METHODS

Protocol, eligibility criteria, information sources and search
This review was performed according to an a-priori-designed protocol recommended for systematic reviews and meta-analyses 10 . MEDLINE, EMBASE and CINAHL were searched electronically on 17 December 2017 and updated on 17 July 2018, utilizing combinations of the relevant medical subject heading (MeSH) terms, keywords and word variants for 'monoamniotic', 'twin pregnancies' and 'outcome' (Table S1 ). The search and selection criteria were restricted to the English language. Reference lists of relevant articles and reviews were hand-searched for additional reports. PRISMA and MOOSE guidelines were followed 11, 12 . The study was registered with the PROSPERO database (registration number: CRD42016043062).
Study selection, data collection and data items
The primary outcome explored in the present systematic review was the incidence of intrauterine death (IUD), neonatal death (NND) and perinatal death (PND) in MCMA twins in the following gestational age windows: 24-30 weeks, 31-32 weeks, 33-34 weeks, 35-36 weeks and ≥ 37 weeks.
IUD was defined as fetal demise from 24 weeks of gestation and was divided into single (sIUD) and double (dIUD) according to the death of one or both twins, respectively. NND was defined as the death of at least one of the newborns up to 28 days postpartum, while PND was defined as IUD plus NND. We also aimed to categorize the cause of IUD into those related to the presence of TTTS or growth restriction and those that were sudden or unexpected, defined as IUD occurring in a MCMA twin without a prior recognizable chronic condition such as transfusion events or growth abnormalities.
The secondary outcomes were the incidence of IUD, NND and PND in twins according to the type of fetal monitoring. For the purpose of this analysis, twin pregnancies were divided into those admitted electively to the hospital for fetal monitoring (inpatients) and those followed up as outpatients. Finally, we explored the incidence of delivery ahead of schedule in MCMA twin pregnancies scheduled for elective delivery at 32 weeks and those scheduled for delivery between 32 and 34 weeks of gestation.
Only studies reporting the number of MCMA twin pregnancies in each gestational-age window and the relative number of deaths were considered suitable for inclusion. Studies including cases with fetal anomaly were excluded in view of the higher risk of mortality in twins affected by structural or chromosomal anomaly. Only full-text articles were considered eligible for inclusion. Case reports, conference abstracts and case series with fewer than three cases were excluded to avoid publication bias. Furthermore, studies published before 2000 were not included, as advances in management of twin pregnancies make them less relevant.
Two authors (F.D., D.B.) reviewed all abstracts independently. Agreement regarding potential relevance was reached by consensus; full-text copies of those papers were obtained and the same two reviewers independently extracted relevant data regarding study characteristics and pregnancy outcome. Inconsistencies were discussed by the reviewers and consensus was reached between them or by discussion with a third author. If more than one study was published on the same cohort with identical endpoints, the report containing the most comprehensive information on the population was included to avoid overlapping populations. For those articles in which information was not reported but the methodology was such to suggest that this information would have been recorded initially, the authors were contacted.
Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for case-control studies. According to NOS, each study is judged on three broad perspectives: selection of the study groups, comparability of the groups and ascertainment of the outcome of interest 13 . Assessment of the selection of a study includes the evaluation of the representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and demonstration that the outcome of interest was not present at the start of study. Assessment of the comparability of the study includes evaluation of the comparability of cohorts based on the design or analysis. Finally, ascertainment of the outcome of interest includes evaluation of the type of assessment of the outcome of interest, length and adequacy of follow-up. According to NOS, a study can be awarded a maximum of one star for each numbered item within the selection and outcome categories. A maximum of two stars can be given for comparability 13 .
Statistical analysis
The prevalence of each of the explored outcomes was evaluated in MCMA twins, overall and according to gestational age; the overall number of fetuses was used as the denominator for each proportion. Proportion meta-analysis using a random-effects model to account for interstudy heterogeneity was used to analyze the data. Potential publication bias was assessed either graphically, displaying the odds ratios of individual studies vs the logarithm of their standard errors (funnel plots), or formally, using Egger's regression asymmetry test 14 . Tests for publication bias were not performed when the overall number of included studies was less than 10, in view of their low power 15 . All analyses were carried out using STATA, version 13.1 (Stata Corp., College Station, TX, USA).
RESULTS
General characteristics
A total of 607 articles were identified and assessed with respect to their eligibility for inclusion. Of those, 53 had the full text assessed for eligibility and 25 were included in the systematic review (Table 1, Figure 1 ) . Table S2 lists the excluded studies and the reason for exclusion. The 25 studies included 1068 MCMA pregnancies (2136 twins); information on perinatal mortality according to the gestational age at loss was provided for 814 non-anomalous twin pairs (1628 twins) reaching 24 weeks of gestation, which represent the population analyzed in this systematic review. Only first author is given for each study. GA, gestational age; NS, not stated; Retro, retrospective. 16 Glinianaia (2019) 17 Kristiansen (2015) 18 Prefumo (2015) 19 Anselem (2015) 20 Van Mieghem (2014) 21 Aurioles-Garibay (2014) 22 Murata (2013) 23 Suzuki (2013) 24 Dias (2011) 25 Quinn (2011) 26 Assuncao (2010) 27 Baxi (2010) 28 Hack (2009) 29 Arabin (2009) 39 Sebire (2000) 40
Only first author is given for each study. Study can be awarded maximum of one star for each numbered item within selection and outcome categories. Maximum of two stars can be given for comparability.
The results of quality assessment of the included studies using the NOS are presented in Table 2 . Most of the included studies showed an overall good score regarding the selection and comparability of the study groups, as well as for ascertainment of the outcome of interest. The main weaknesses of these studies were their retrospective design, small sample size, different gestational ages at ultrasound examination and lack of information on prenatal management of twins affected by weight discordance.
Synthesis of results
Twenty-four studies including 814 non-anomalous MCMA pregnancies (1628 twins) reaching 24 weeks of gestation explored the incidence of mortality according to gestational age. Overall IUD, including either sIUD or dIUD, occurred in 5.8% (95% CI, 4.0-8.1%) of twins, while the corresponding figures for sIUD and dIUD were 2.5% (95% CI, 1.8-3.3%) and 3.8% (95% CI, 2.5-5.3%). The incidence of NND was 2.6% (95% CI, 1.9-3.4%) (Table 3, Figure 2 ).
The incidence of mortality varied according to gestational-age window. IUD occurred in 4.3% (95% Kristiansen (2015) 18 Prefumo (2015) 19 Anselem (2015) 20 Van Mieghem (2014) 21 Murata (2013) 23 Suzuki (2013) 24 Aurioles-Garibay (2014) 22 Dias (2011) 25 Quinn (2011) 26 Assuncao (2010) 27 Baxi (2010) 28 Hack (2009) 29 Arabin (2009) 30 Heflin (2008) 31 Cordero (2006) CI, 2.8-6.2%) of cases at 24-30 weeks, 1.0% (95% CI, 0.6-1.7%) at 31-32 weeks and in 2.2% (95% CI, 0.9-3.9%) at 33-34 weeks of gestation, while there was no IUD, either single or double, from 35 weeks of gestation, although the sample size was small (Table 3, Figure 3 ). sIUD and dIUD occurred, respectively, in 2.0% (95% CI, 1.4-2.7%) and 2.9% (95% CI, 1.8-4.2%) of twins at 24-30 weeks, 0.6% (95% CI, 0.2-1.1%) and 0.7% (95% CI, 0.3-1.2%) at 31-32 weeks, and 1.0% (95% CI, 0.4-1.9%) and 1.6% (95% CI, 0.6-3.0%) of cases at 33-34 weeks of gestation. Finally, NND occurred in 2.5% (95% CI, 1.8-3.3%) of cases at 24-30 weeks and 0.6% (95% CI, 0.2-1.1%) at 31-32 weeks, while there was no death later in gestation (Table 3) .
When analyzing those studies reporting the etiology of IUD, 29.5% (95% CI, 13.5-48.8%; I 2 = 55.2%) of the overall losses were due to TTTS or growth restriction, while 54.0% (95% CI, 37.1-71.3%; I 2 = 42.8%) were unexpected IUD. Furthermore, from 31 weeks of Saccone (2019) 16 Prefumo (2015) 19 Van Mieghem (2014) 21 Murata (2013) 23 Aurioles-Garibay (2014) 22 Quinn (2011) 26 Baxi (2010) 28 Hack (2009) 29 DeFalco (2006) 34 Heyborne (2005) 35 Ezra (2005) 36 Allen (2001) 39 Combined Saccone (2019) 16 Kristiansen (2015) 18 Anselem (2015) 20 Van Mieghem (2014) 21 Dias (2011) 25 Hack (2009) 29 Heflin (2008) 31 Pasquini (2006) 33 DeFalco (2006) 34 Heyborne (2005) 35 Ezra (2005) 36 Demaria (2004) 37 Sau (2003) 38 Allen (2001) gestation, all IUDs included in the present systematic review were reported to be unexpected and not the consequence of a chronic condition that can be potentially identified in utero. Twenty studies reported the incidence of mortality in pregnancies managed mainly as inpatients and/or those followed up as outpatients. In MCMA twin pregnancies managed mainly as inpatients, the incidence of IUD was 3.0% (95% CI, 1.4-5.2%), while the corresponding figures for sIUD and dIUD were 1.9% (95% CI, 0.9-3.1%) and 1.6% (95% CI, 0.5-3.3%) (Figure 4 , Table 4 ). Conversely, in MCMA twin pregnancies managed mainly as outpatients, IUD occurred in 7.4% (95% CI, 4.4-11.1%) of twins, while sIUD and dIUD occurred in 2.4% (95% CI, 1.2-4.0%) and 5.3% (95% CI, 3.2-8.0%), respectively.
In pregnancies managed mainly as inpatients, 27.9% (95% CI, 10.4-49.9%; I 2 = 0%) of the IUDs were due Finally, the rate of delivery ahead of schedule was explored. Overall, 37.8% (95% CI, 28.0-48.2%) of MCMA pregnancies were delivered before the scheduled time, due mainly to spontaneous preterm labor or abnormal CTG findings. In MCMA twin pregnancies scheduled for delivery at 32 weeks of gestation, the rate of delivery before this time was 18.5% (95% CI, 6.5-34.8%), while the corresponding figure for those scheduled between 32 and 34 weeks was 34.7% (95% CI, 26.6-43.2%) ( Table 5) . When stratifying the analysis according to the type of prenatal management adopted, the risk of unexpected delivery was 44.9% (95% CI, 28.7-61.6%) and 42.3% (95% CI, 26.4-59.4%) in pregnancies managed mainly as inpatients and those managed mainly as outpatients, respectively. In pregnancies managed mainly as inpatients, 22.7% (95% CI, 10.3-38.2%) and 44.9% (95% CI, 28.7-61.6%) of unexpected deliveries were due to preterm birth and CTG abnormalities, respectively, while the corresponding figures for pregnancies managed mainly as outpatients were 16.4% (95% CI, 10.4-23.4%) and 16.7% (95% CI, 5.9-31.4%).
DISCUSSION
Main findings
The findings of this systematic review show that the overall incidence of fetal loss in MCMA pregnancies is approximately 6%. The large majority of fetal losses occurred before 30 weeks of gestation, while the risk of demise at 31-32 and 33-34 weeks of gestation was 1% and 2%, respectively. Most IUDs were unexpected, thus questioning the optimal type of assessment in these pregnancies. Finally, the incidence of fetal loss in twins of pregnancies managed mainly as inpatients was 3% as compared with 7% in those followed up as outpatients. Despite this, the heterogeneity in the type of prenatal assessment among the included studies highlights the need for developing an adequate protocol for prenatal management of MCMA twin pregnancies, focusing on the type and frequency of follow-up rather than admission to the hospital.
Strengths and limitations
The small number of cases in some of the included studies, their retrospective non-randomized design, dissimilarity of the populations (due to varied inclusion criteria) and lack of standardized criteria for the antenatal management of MCMA twin pregnancies represent the major limitations of this systematic review. Assessment of potential publication bias was also problematic because of the nature of the outcome evaluated (outcome rates, with the left-side limited to a value of zero), which limits the reliability of funnel plots, and because of the scarce number of individual studies, which strongly limits the reliability of formal tests. Another major limitation of this systematic review is represented by differences in the antenatal management of MCMA pregnancies in terms of type and frequency of assessment. Despite these limitations, the present review represents the most comprehensive published estimate of the investigated outcomes in MCMA twin pregnancies.
Implications for clinical practice
Management of MCMA twin pregnancy is challenging. As there are no randomized trials assessing the optimal prenatal management of MCMA pregnancies in terms of type and frequency of follow-up and gestational age at delivery, it is not possible to provide specific recommendations on how to manage these pregnancies.
It is true that MCMA twins are rare; however, prenatal identification of those pregnancies is fundamental in their risk stratification and tailoring their antenatal care 4 . In the present systematic review, only 30% of IUDs were due to recognizable conditions such as TTTS or growth abnormalities, while the large majority of them occurred unexpectedly. However, prenatal diagnosis of TTTS in MCMA twin pregnancy is challenging and not based upon classical ultrasound features observed in these pregnancies. Polyhydramnios and non-visualization of the bladder in one of the twins are usually the first signs of TTTS in MCMA twin pregnancy. In this scenario, it may be entirely possible that some of the fetal losses labeled as unexpected were the result of undiagnosed TTTS. This highlights the need for thorough regular examination of MCMA twins in order to look for signs of TTTS, such as amniotic fluid volume, visualization of the bladder and fetal Doppler.
Timing of delivery of apparently uncomplicated MCMA twins is still debated. It is common practice to deliver MCMA twins between 32 and 34 weeks of gestation, in view of the reported high risk of IUD in the third trimester of pregnancy. However, most of the previously published studies included fetuses with anomalies, which are at higher risk of fetal loss, and come from an era in which the natural history of TTTS had not been systematically elucidated, thus explaining the high rate of deaths labeled as unexpected in otherwise apparently uncomplicated MCMA twins.
The findings of this review showed that fetal loss occurs in 1% of MCMA twins at 31-32 weeks and 2% at 33-34 weeks of gestation; furthermore, double fetal demises affected about 2% of twins at 33-34 weeks of gestation, thus highlighting the need for a thorough follow-up if the pregnancy is continued beyond 32 weeks. A policy of elective delivery at 32 weeks of gestation may look appropriate in view of the apparently higher risk of fetal demise occurring later on in gestation, but should be balanced against the potentially higher risk of neonatal morbidity. However, a large proportion of MCMA twins will be delivered before the scheduled time, especially as a consequence of spontaneous preterm labor.
The type of prenatal follow-up of MCMA twin pregnancy is also controversial. Some studies claim that elective admission to the hospital in the third trimester may improve the outcome of MCMA pregnancy, while others have shown no difference. Furthermore, there is as yet no consensus on when to start intensive follow-up and monitoring.
In the present systematic review, the incidence of fetal loss was 3% in twins of pregnancies managed mainly as inpatients compared with 7% in those of pregnancies followed up as outpatients. However, there was significant heterogeneity in the management protocols among the included studies, which might have biased the results. Furthermore, comparison between inpatient and outpatient monitoring was affected by the largest study included in the analysis 16 . In that study, outpatient surveillance was started at 30 weeks for the majority of included centers, whereas inpatient surveillance was started at 24 weeks. Deaths in the outpatient group occurred before 30 weeks (i.e. before initiation of surveillance), while after 30 weeks, the number of deaths in the inpatient and outpatient cohorts was very similar (1.4 vs 2.4%).
The perinatal outcome of MC pregnancies is dependent not only on the degree of placental sharing between the twins but also on the direction and the magnitude of blood flow through the intertwin anastomoses. MCMA twins have a lower risk of developing TTTS compared with MCDA pregnancies due to their peculiar vascular arrangement with nearby placental insertions of the umbilical cords and the large arterioarterial anastomoses. However, acute unpredictable transfusion events can still occur 3 . An adequate prenatal management of monoamniotic twins should include serial assessment of the amniotic fluid, fetal urinary bladders and Doppler studies to rule out signs of TTTS. It is unclear whether systematic evaluation of umbilical cords to diagnose entanglement may reduce the risk of fetal loss, as many of them are acute events that may not be easily predicted. Regarding the frequency of fetal monitoring, a twice-weekly scan starting from 24-26 weeks of gestation has been proposed in view of the high rate of perinatal loss occurring at 24-30 weeks of gestation. Despite this, parental counseling should stress the fact that a normal scan cannot completely rule out adverse events, as they may occur acutely.
Further large studies are needed in order to develop objective protocols for antenatal surveillance of MCMA twins, aiming at reducing the risk of perinatal mortality and morbidity in these pregnancies. Considering the occurrence of IUD in the subgroups of MCMA pregnancies managed as inpatients and those managed as outpatients (3.02% and 7.40%, respectively), a minimum of 806 (403 per group) pregnancies would be needed to find a difference in mortality according to the two management options, with a power of 80% and an alpha error of 0.05.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Search strategy for articles on outcome of monochorionic monoamniotic twin pregnancy This article has been selected for Journal Club.
Mortalidad perinatal, momento del parto y tratamiento prenatal del embarazo gemelar monoamniótico: revisión sistemática y metaanálisis RESUMEN Objetivo Cuantificar la tasa de mortalidad perinatal en los embarazos gemelares monocoriónicos monoamnióticos (MCMA), en función de la edad gestacional, y determinar la incidencia de la mortalidad en los embarazos atendidos en pacientes hospitalizadas en comparación con los atendidos en pacientes ambulatorias.
Métodos Se realizaron búsquedas en las bases de datos de MEDLINE, EMBASE y CINAHL dirigidas a estudios sobre embarazo gemelar monoamniótico. Las medidas de resultados primarios examinadas fueron (todas las siglas del inglés) la incidencia de muerte intrauterina (IUD), la muerte neonatal (NND) y la muerte perinatal (PND) en gemelos MCMA en diferentes edades gestacionales (24-30, 31-32, 33-34, 35-36 y ≥ 37 semanas de gestación). Las medidas de resultados secundarios fueron la incidencia de IUD, NND y PND en los gemelos MCMA según el tipo de monitorización fetal (paciente hospitalizada frente a paciente ambulatoria) y la incidencia de parto pretérmino. Para analizar los datos se utilizaron metaanálisis de modelo de efectos aleatorios.
Resultados Se incluyeron 25 estudios (1628 gemelos no anómalos que alcanzaron las 24 semanas de gestación). Las muertes intrauterinas simples (sIUD) y dobles (dIUD) ocurrieron en el 2,5% (IC 95%: 1,8-3,3%) y el 3,8% (IC 95%: 2,5-5,3%) de los casos, respectivamente. La IUD ocurrió en el 4,3% (IC 95%: 2,8-6,2%) de los gemelos a las 24-30 semanas de gestación, en el 1,0% (IC 95%: 0,6-1,7%) a las 31-32 semanas y en el 2,2% (IC 95%: 0,9-3,9%) a las 33-34 semanas, mientras que no hubo ningún caso de IUD, ya fuera simple o doble, a partir de las 35 semanas de gestación. En los embarazos gemelares MCMA tratados principalmente como pacientes hospitalizadas, la incidencia de la IUD fue del 3,0% (IC 95%: 1,4-5,2%), mientras que la cifra correspondiente para las que se trataron principalmente como pacientes ambulatorias fue del 7,4% (IC 95%: 4,4-11,1%). Finalmente, el parto del 37,8% (IC 95%, 28,0-48,2%) de los embarazos MCMA fue antes del momento programado, debido principalmente a parto pretérmino espontáneo o a hallazgos anómalos en la CTG.
Conclusiones Los gemelos MCMA tienen un alto riesgo de pérdida perinatal durante el tercer trimestre del embarazo, y la gran mayoría de estas pérdidas ocurren como eventos aparentemente inesperados. El tratamiento hospitalario parece estar asociado con una menor tasa de mortalidad, aunque se necesitan estudios adicionales para establecer el tipo y el momento adecuado de la evaluación prenatal en estos embarazos.
